

AN ACT

1  
2 relating to controlled substance prescriptions and reimbursement  
3 for treatment for certain substance use disorders; authorizing a  
4 fee.

5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

6 SECTION 1. Section 552.118, Government Code, is amended to  
7 read as follows:

8 Sec. 552.118. EXCEPTION: CONFIDENTIALITY OF OFFICIAL  
9 PRESCRIPTION PROGRAM INFORMATION. Information is excepted from the  
10 requirements of Section 552.021 if it is:

11 (1) information on or derived from an official  
12 prescription form filed with the Texas State Board of Pharmacy  
13 under Section 481.0755, Health and Safety Code, or an electronic  
14 prescription record filed with the Texas State Board of Pharmacy  
15 under Section 481.075, Health and Safety Code; or

16 (2) other information collected under Section 481.075  
17 or 481.0755 of that code.

18 SECTION 2. Sections 481.002(10) and (47), Health and Safety  
19 Code, are amended to read as follows:

20 (10) "Designated agent" means an individual  
21 designated under Section 481.074(b-2) [~~481.073~~] to communicate a  
22 practitioner's instructions to a pharmacist in an emergency.

23 (47) "Official prescription form" means a  
24 prescription form that is used for a Schedule II controlled

1 substance under Section 481.0755 and contains the prescription  
2 information required by Section 481.0755(e) [~~481.075~~].

3 SECTION 3. Section 481.003(a), Health and Safety Code, is  
4 amended to read as follows:

5 (a) The director may adopt rules to administer and enforce  
6 this chapter, other than Sections [~~481.073,~~] 481.074, 481.075,  
7 481.0755, 481.0756, 481.076, 481.0761, 481.0762, 481.0763,  
8 481.07635, 481.07636, 481.0764, 481.0765, and 481.0766. The board  
9 may adopt rules to administer Sections [~~481.073,~~] 481.074, 481.075,  
10 481.0755, 481.0756, 481.076, 481.0761, 481.0762, 481.0763,  
11 481.07635, 481.07636, 481.0764, 481.0765, and 481.0766.

12 SECTION 4. Section 481.074, Health and Safety Code, is  
13 amended by amending Subsections (b), (c), (e), (f), (g), (h), (k),  
14 and (q) and adding Subsections (b-1) and (b-2) to read as follows:

15 (b) Except in an emergency as defined by board rule under  
16 Subsection (b-1) [~~of the board~~] or as otherwise provided by  
17 [~~Subsection (e) or~~] Section 481.075(j) or (m) or 481.0755, a person  
18 may not dispense or administer a controlled substance [~~listed in~~  
19 ~~Schedule II without a written prescription of a practitioner on an~~  
20 ~~official prescription form or~~] without an electronic prescription  
21 that meets the requirements of and is completed by the practitioner  
22 in accordance with Section 481.075.

23 (b-1) In an emergency as defined by board rule, a person may  
24 dispense or administer a controlled substance [~~listed in Schedule~~  
25 ~~II~~] on the oral or telephonically communicated prescription of a  
26 practitioner. The person who administers or dispenses the  
27 substance shall:

1 (1) if the person is a prescribing practitioner or a  
2 pharmacist, promptly comply with Subsection (c); or

3 (2) if the person is not a prescribing practitioner or  
4 a pharmacist, promptly write the oral or telephonically  
5 communicated prescription and include in the written record of the  
6 prescription the name, address, and Federal Drug Enforcement  
7 Administration number issued for prescribing a controlled  
8 substance in this state of the prescribing practitioner, all  
9 information required to be provided by a practitioner under Section  
10 481.075(e)(1), and all information required to be provided by a  
11 dispensing pharmacist under Section 481.075(e)(2).

12 (b-2) In an emergency described by Subsection (b-1), an  
13 agent designated in writing by a practitioner defined by Section  
14 481.002(39)(A) may communicate a prescription by telephone. A  
15 practitioner who designates a different agent shall designate that  
16 agent in writing and maintain the designation in the same manner in  
17 which the practitioner initially designated an agent under this  
18 subsection. On the request of a pharmacist, a practitioner shall  
19 furnish a copy of the written designation. This subsection does not  
20 relieve a practitioner or the practitioner's designated agent from  
21 the requirement of Subchapter A, Chapter 562, Occupations Code. A  
22 practitioner is personally responsible for the actions of the  
23 designated agent in communicating a prescription to a pharmacist.

24 (c) Not later than the seventh day after the date a  
25 prescribing practitioner authorizes an emergency oral or  
26 telephonically communicated prescription, the prescribing  
27 practitioner shall cause an [~~a written or~~] electronic prescription,

1 completed in the manner required by Section 481.075, to be  
2 delivered to the dispensing pharmacist at the pharmacy where the  
3 prescription was dispensed. ~~[A written prescription may be  
4 delivered in person or by mail. The envelope of a prescription  
5 delivered by mail must be postmarked not later than the seventh day  
6 after the date the prescription was authorized. On receipt of a  
7 written prescription, the dispensing pharmacy shall file the  
8 transcription of the telephonically communicated prescription and  
9 the pharmacy copy and shall send information to the board as  
10 required by Section 481.075.]~~ On receipt of the [an] electronic  
11 prescription, the pharmacist shall annotate the electronic  
12 prescription record with the original authorization and date of the  
13 emergency oral or telephonically communicated prescription.

14 (e) The partial filling of a prescription for a controlled  
15 substance listed in Schedule II is permissible in accordance with  
16 applicable federal law~~[, if the pharmacist is unable to supply the  
17 full quantity called for in a written or electronic prescription or  
18 emergency oral prescription and the pharmacist makes a notation of  
19 the quantity supplied on the face of the written prescription, on  
20 the written record of the emergency oral prescription, or in the  
21 electronic prescription record. The remaining portion of the  
22 prescription may be filled within 72 hours of the first partial  
23 filling; however, if the remaining portion is not or cannot be  
24 filled within the 72-hour period, the pharmacist shall so notify  
25 the prescribing individual practitioner. No further quantity may  
26 be supplied beyond 72 hours without a new prescription].~~

27 (f) A prescription for a Schedule II controlled substance

1 for a patient in a long-term care facility (LTCF) or for a hospice  
2 patient with a medical diagnosis documenting a terminal illness may  
3 be filled in partial quantities to include individual dosage units.  
4 If there is any question about whether a hospice patient may be  
5 classified as having a terminal illness, the pharmacist must  
6 contact the practitioner before partially filling the  
7 prescription. Both the pharmacist and the practitioner have a  
8 corresponding responsibility to assure that the controlled  
9 substance is for a terminally ill hospice patient. The pharmacist  
10 must record the prescription [~~on an official prescription form or~~  
11 in the electronic prescription record and must indicate [~~on the~~  
12 ~~official prescription form or~~] in the electronic prescription  
13 record whether the patient is a "terminally ill hospice patient" or  
14 an "LTCF patient." A prescription that is partially filled and does  
15 not contain the notation "terminally ill hospice patient" or "LTCF  
16 patient" is considered to have been filled in violation of this  
17 chapter. For each partial filling, the dispensing pharmacist shall  
18 record [~~on the back of the official prescription form or~~] in the  
19 electronic prescription record the date of the partial filling, the  
20 quantity dispensed, the remaining quantity authorized to be  
21 dispensed, and the identification of the dispensing pharmacist.  
22 Before any subsequent partial filling, the pharmacist must  
23 determine that the additional partial filling is necessary. The  
24 total quantity of Schedule II controlled substances dispensed in  
25 all partial fillings may not exceed the total quantity prescribed.  
26 Schedule II prescriptions for patients in a long-term care facility  
27 or hospice patients with a medical diagnosis documenting a terminal

1 illness are valid for a period not to exceed 60 days following the  
2 issue date unless sooner terminated by discontinuance of the  
3 medication.

4 (g) A person may not dispense a controlled substance in  
5 Schedule III or IV that is a prescription drug under the Federal  
6 Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.) without  
7 a [~~written, electronic, oral, or telephonically communicated~~]  
8 prescription of a practitioner defined by Section 481.002(39)(A) or  
9 (D), except that the practitioner may dispense the substance  
10 directly to an ultimate user. A prescription for a controlled  
11 substance listed in Schedule III or IV may not be filled or refilled  
12 later than six months after the date on which the prescription is  
13 issued and may not be refilled more than five times, unless the  
14 prescription is renewed by the practitioner. A prescription under  
15 this subsection must comply with other applicable state and federal  
16 laws.

17 (h) A pharmacist may dispense a controlled substance listed  
18 in Schedule III, IV, or V under a [~~written, electronic, oral, or~~  
19 ~~telephonically communicated~~] prescription issued by a practitioner  
20 defined by Section 481.002(39)(C) [~~and~~] only if the pharmacist  
21 determines that the prescription was issued for a valid medical  
22 purpose and in the course of professional practice. A prescription  
23 described by [~~issued under~~] this subsection may not be filled or  
24 refilled later than six months after the date the prescription is  
25 issued and may not be refilled more than five times, unless the  
26 prescription is renewed by the practitioner.

27 (k) A prescription for a controlled substance must show:

1 (1) the quantity of the substance prescribed:

2 (A) [~~numerically, followed by the number written~~  
3 ~~as a word, if the prescription is written,~~

4 [~~(B)~~] numerically, if the prescription is  
5 electronic; or

6 (B) [~~(C)~~] if the prescription is communicated  
7 orally or telephonically, as transcribed by the receiving  
8 pharmacist;

9 (2) the date of issue;

10 (2-a) if the prescription is issued for a Schedule II  
11 controlled substance to be filled at a later date under Subsection  
12 (d-1), the earliest date on which a pharmacy may fill the  
13 prescription;

14 (3) the name, address, and date of birth or age of the  
15 patient or, if the controlled substance is prescribed for an  
16 animal, the species of the animal and the name and address of its  
17 owner;

18 (4) the name and strength of the controlled substance  
19 prescribed;

20 (5) the directions for use of the controlled  
21 substance;

22 (6) the intended use of the substance prescribed  
23 unless the practitioner determines the furnishing of this  
24 information is not in the best interest of the patient; and

25 (7) the name, address, Federal Drug Enforcement  
26 Administration number, and telephone number of the practitioner at  
27 the practitioner's usual place of business [~~, which must be legibly~~

1 ~~printed or stamped on a written prescription, and~~  
2  ~~[(8) if the prescription is handwritten, the signature~~  
3  ~~of the prescribing practitioner].~~

4 (q) Each dispensing pharmacist shall send all required  
5 information~~[, including any information required to complete the~~  
6  ~~Schedule III through V prescription forms,]~~ to the board by  
7 electronic transfer or another form approved by the board not later  
8 than the next business day after the date the prescription is  
9 completely filled.

10 SECTION 5. The heading to Section [481.075](#), Health and  
11 Safety Code, is amended to read as follows:

12 Sec. 481.075. SCHEDULE II PRESCRIPTIONS ~~[OFFICIAL~~  
13 ~~PRESCRIPTION PROGRAM]~~.

14 SECTION 6. Sections [481.075](#)(a), (e), (g), (h), (i), and  
15 (j), Health and Safety Code, are amended to read as follows:

16 (a) A practitioner who prescribes a controlled substance  
17 listed in Schedule II shall, except as provided by Section  
18 [481.074](#)(b-1) or [481.0755](#) or a rule adopted under Section [481.0761](#),  
19 record the prescription ~~[on an official prescription form or]~~ in an  
20 electronic prescription that includes the information required by  
21 this section.

22 (e) Each ~~[official prescription form or electronic]~~  
23 prescription used to prescribe a Schedule II controlled substance  
24 must contain:

25 (1) information provided by the prescribing  
26 practitioner, including:

27 (A) the date the prescription is issued;



1 (B) the controlled substance prescribed;

2 (C) the quantity of controlled substance  
3 prescribed, shown~~+~~

4 [~~(i)~~] numerically~~[, followed by the number~~  
5 ~~written as a word, if the prescription is written, or~~

6 [~~(ii)~~ numerically, if the prescription is  
7 ~~electronic~~];

8 (D) the intended use of the controlled substance,  
9 or the diagnosis for which the controlled substance [~~it~~] is  
10 prescribed, and the instructions for use of the substance;

11 (E) the practitioner's name, address, and  
12 Federal Drug Enforcement Administration number issued for  
13 prescribing a controlled substance in this state;

14 (F) the name, address, and date of birth or age of  
15 the person for whom the controlled substance is prescribed; and

16 (G) if the prescription is issued to be filled at  
17 a later date under Section 481.074(d-1), the earliest date on which  
18 a pharmacy may fill the prescription;

19 (2) information provided by the dispensing  
20 pharmacist, including the date the prescription is filled; and

21 (3) [~~for a written prescription, the signatures of the~~  
22 ~~prescribing practitioner and the dispensing pharmacist or for an~~  
23 ~~electronic prescription,~~] the prescribing practitioner's  
24 electronic signature or other secure method of validation  
25 authorized by federal law.

26 (g) Except for an emergency oral or telephonically  
27 communicated prescription described by [~~prescribed under~~] Section

1 481.074(b-1) [~~481.074(b)~~], the prescribing practitioner shall:

2 (1) record [~~legibly fill in,~~] or direct a designated  
3 agent to record [~~legibly fill in, on the official prescription form~~  
4 ~~or~~] in the electronic prescription[~~]~~ each item of information  
5 required to be provided by the prescribing practitioner under  
6 Subsection (e)(1), unless the practitioner determines that:

7 (A) under rule adopted by the board for this  
8 purpose, it is unnecessary for the practitioner or the  
9 practitioner's agent to provide the patient identification number;  
10 or

11 (B) it is not in the best interest of the patient  
12 for the practitioner or practitioner's agent to provide information  
13 regarding the intended use of the controlled substance or the  
14 diagnosis for which it is prescribed; and

15 (2) [~~sign the official prescription form and give the~~  
16 ~~form to the person authorized to receive the prescription or, in the~~  
17 ~~case of an electronic prescription,~~] electronically sign or  
18 validate the electronic prescription as authorized by federal law  
19 and transmit the prescription to the dispensing pharmacy.

20 (h) In the case of an emergency oral or telephonically  
21 communicated prescription described by [~~prescribed under~~] Section  
22 481.074(b-1) [~~481.074(b)~~], the prescribing practitioner shall give  
23 the dispensing pharmacy the information needed to complete the  
24 [~~official prescription form or~~] electronic prescription record.

25 (i) Each dispensing pharmacist shall:

26 (1) [~~fill in on the official prescription form or~~]  
27 note in the electronic prescription record each item of information

1 given orally to the dispensing pharmacy under Subsection (h) and  
2 the date the prescription is filled~~[,]~~ and~~[+]~~

3 ~~[(A) for a written prescription, fill in the~~  
4 ~~dispensing pharmacist's signature, or~~

5 ~~[(B) for an electronic prescription,]~~  
6 appropriately record the identity of the dispensing pharmacist in  
7 the electronic prescription record;

8 (2) retain with the records of the pharmacy for at  
9 least two years:

10 (A) ~~[the official prescription form or]~~ the  
11 electronic prescription record~~[, as applicable]; and~~

12 (B) the name or other patient identification  
13 required by Section 481.074(m) or (n); and

14 (3) send all required information, including any  
15 information required to complete an ~~[official prescription form or]~~  
16 electronic prescription record, to the board by electronic transfer  
17 or another form approved by the board not later than the next  
18 business day after the date the prescription is completely filled.

19 (j) A medication order written for a patient who is admitted  
20 to a hospital at the time the medication order is written and filled  
21 is not required to be recorded ~~[on an official prescription form or]~~  
22 in an electronic prescription record that meets the requirements of  
23 this section.

24 SECTION 7. Subchapter C, Chapter 481, Health and Safety  
25 Code, is amended by adding Sections 481.0755 and 481.0756 to read as  
26 follows:

27 Sec. 481.0755. WRITTEN, ORAL, AND TELEPHONICALLY

1 COMMUNICATED PRESCRIPTIONS. (a) Notwithstanding Sections 481.074  
2 and 481.075, a prescription for a controlled substance is not  
3 required to be issued electronically and may be issued in writing if  
4 the prescription is issued:

5 (1) by a veterinarian;

6 (2) in circumstances in which electronic prescribing  
7 is not available due to temporary technological or electronic  
8 failure, as prescribed by board rule;

9 (3) by a practitioner to be dispensed by a pharmacy  
10 located outside this state, as prescribed by board rule;

11 (4) when the prescriber and dispenser are in the same  
12 location or under the same license;

13 (5) in circumstances in which necessary elements are  
14 not supported by the most recently implemented national data  
15 standard that facilitates electronic prescribing;

16 (6) for a drug for which the United States Food and  
17 Drug Administration requires additional information in the  
18 prescription that is not possible with electronic prescribing;

19 (7) for a non-patient-specific prescription pursuant  
20 to a standing order, approved protocol for drug therapy,  
21 collaborative drug management, or comprehensive medication  
22 management, in response to a public health emergency or in other  
23 circumstances in which the practitioner may issue a  
24 non-patient-specific prescription;

25 (8) for a drug under a research protocol;

26 (9) by a practitioner who has received a waiver under  
27 Section 481.0756 from the requirement to use electronic

1 prescribing;

2 (10) under circumstances in which the practitioner has  
3 the present ability to submit an electronic prescription but  
4 reasonably determines that it would be impractical for the patient  
5 to obtain the drugs prescribed under the electronic prescription in  
6 a timely manner and that a delay would adversely impact the  
7 patient's medical condition; or

8 (11) before January 1, 2021.

9 (b) A dispensing pharmacist who receives a controlled  
10 substance prescription in a manner other than electronically is not  
11 required to verify that the prescription is exempt from the  
12 requirement that it be submitted electronically. The pharmacist  
13 may dispense a controlled substance pursuant to an otherwise valid  
14 written, oral, or telephonically communicated prescription  
15 consistent with the requirements of this subchapter.

16 (c) Except in an emergency, a practitioner must use a  
17 written prescription to submit a prescription described by  
18 Subsection (a). In an emergency, the practitioner may submit an  
19 oral or telephonically communicated prescription as authorized  
20 under Section [481.074\(b-1\)](#).

21 (d) A written prescription for a controlled substance other  
22 than a Schedule II controlled substance must include the  
23 information required under Section [481.074\(k\)](#) and the signature of  
24 the prescribing practitioner.

25 (e) A written prescription for a Schedule II controlled  
26 substance must be on an official prescription form and include the  
27 information required for an electronic prescription under Section

1 481.075(e), the signature of the practitioner, and the signature of  
2 the dispensing pharmacist after the prescription is filled.

3 (f) The board by rule shall authorize a practitioner to  
4 determine whether it is necessary to obtain a particular patient  
5 identification number and to provide that number on the official  
6 prescription form.

7 (g) On request of a practitioner, the board shall issue  
8 official prescription forms to the practitioner for a fee covering  
9 the actual cost of printing, processing, and mailing the forms.  
10 Before mailing or otherwise delivering prescription forms to a  
11 practitioner, the board shall print on each form the number of the  
12 form and any other information the board determines is necessary.

13 (h) Each official prescription form must be sequentially  
14 numbered.

15 (i) A person may not obtain an official prescription form  
16 unless the person is a practitioner as defined by Section  
17 481.002(39)(A) or an institutional practitioner.

18 (j) Not more than one Schedule II prescription may be  
19 recorded on an official prescription form.

20 (k) Not later than the 30th day after the date a  
21 practitioner's Federal Drug Enforcement Administration number or  
22 license to practice has been denied, suspended, canceled,  
23 surrendered, or revoked, the practitioner shall return to the board  
24 all official prescription forms in the practitioner's possession  
25 that have not been used for prescriptions.

26 (l) Each prescribing practitioner:

27 (1) may use an official prescription form only to

1 submit a prescription described by Subsection (a);

2 (2) shall date or sign an official prescription form  
3 only on the date the prescription is issued; and

4 (3) shall take reasonable precautionary measures to  
5 ensure that an official prescription form issued to the  
6 practitioner is not used by another person to violate this  
7 subchapter or a rule adopted under this subchapter.

8 (m) In the case of an emergency oral or telephonically  
9 communicated prescription described by Section 481.074(b-1), the  
10 prescribing practitioner shall give the dispensing pharmacy the  
11 information needed to complete the official prescription form if  
12 the pharmacy is not required to use the electronic prescription  
13 record.

14 (n) Each dispensing pharmacist receiving an oral or  
15 telephonically communicated prescription under Subsection (m)  
16 shall:

17 (1) fill in on the official prescription form each  
18 item of information given orally to the dispensing pharmacy under  
19 Subsection (m) and the date the prescription is filled and fill in  
20 the dispensing pharmacist's signature;

21 (2) retain with the records of the pharmacy for at  
22 least two years:

23 (A) the official prescription form; and

24 (B) the name or other patient identification  
25 required by Section 481.074(m) or (n); and

26 (3) send all required information, including any  
27 information required to complete an official prescription form, to

1 the board by electronic transfer or another form approved by the  
2 board not later than the next business day after the date the  
3 prescription is completely filled.

4 Sec. 481.0756. WAIVERS FROM ELECTRONIC PRESCRIBING. (a)  
5 The appropriate regulatory agency that issued the license,  
6 certification, or registration to a prescriber is authorized to  
7 grant a prescriber a waiver from the electronic prescribing  
8 requirement under the provisions of this section.

9 (b) The board shall convene an interagency workgroup that  
10 includes representatives of each regulatory agency that issues a  
11 license, certification, or registration to a prescriber.

12 (c) The work group described by Subsection (b) shall  
13 establish recommendations and standards for circumstances in which  
14 a waiver from the electronic prescribing requirement is appropriate  
15 and a process under which a prescriber may request and receive a  
16 waiver.

17 (d) The board shall adopt rules establishing the  
18 eligibility for a waiver, including:

19 (1) economic hardship;  
20 (2) technological limitations not reasonably within  
21 the control of the prescriber; or

22 (3) other exceptional circumstances demonstrated by  
23 the prescriber.

24 (e) Each regulatory agency that issues a license,  
25 certification, or registration to a prescriber shall adopt rules  
26 for the granting of waivers consistent with the board rules adopted  
27 under Subsection (d).



1        (f) A waiver may be issued to a prescriber for a period of  
2 one year. A prescriber may reapply for a subsequent waiver not  
3 earlier than the 30th day before the date the waiver expires if the  
4 circumstances that necessitated the waiver continue.

5        SECTION 8. Sections 481.0761(c) and (d), Health and Safety  
6 Code, are amended to read as follows:

7        (c) The board by rule may:

8            (1) ~~[permit more than one prescription to be~~  
9 ~~administered or dispensed and recorded on one prescription form for~~  
10 ~~a Schedule III through V controlled substance;~~

11            [(1-a)] establish a procedure for the issuance of  
12 multiple prescriptions of a Schedule II controlled substance under  
13 Section 481.074(d-1);

14            (2) remove from or return to the official prescription  
15 program any aspect of a practitioner's or pharmacist's hospital  
16 practice, including administering or dispensing;

17            (3) waive or delay any requirement relating to the  
18 time or manner of reporting;

19            (4) establish compatibility protocols for electronic  
20 data transfer hardware, software, or format, including any  
21 necessary modifications for participation in a database described  
22 by Section 481.076(j);

23            (5) establish a procedure to control the release of  
24 information under Sections 481.074, 481.075, and 481.076; and

25            (6) establish a minimum level of prescription activity  
26 below which a reporting activity may be modified or deleted.

27        (d) The board by rule shall authorize a practitioner to

1 determine whether it is necessary to obtain a particular patient  
2 identification number and to provide that number [~~on the official~~  
3 ~~prescription form or~~] in the electronic prescription record.

4 SECTION 9. Subchapter C, Chapter 481, Health and Safety  
5 Code, is amended by adding Sections 481.07635 and 481.07636 to read  
6 as follows:

7 Sec. 481.07635. CONTINUING EDUCATION. (a) A person  
8 authorized to receive information under Section 481.076(a)(5)  
9 shall, not later than the first anniversary after the person is  
10 issued a license, certification, or registration to prescribe or  
11 dispense controlled substances under this chapter, complete two  
12 hours of professional education related to approved procedures of  
13 prescribing and monitoring controlled substances.

14 (b) A person authorized to receive information may annually  
15 take the professional education course under this section to fulfil  
16 hours toward the ethics education requirement of the person's  
17 license, certification, or registration.

18 (c) The regulatory agency that issued the license,  
19 certification, or registration to a person authorized to receive  
20 information under Section 481.076(a)(5) shall approve professional  
21 education to satisfy the requirements of this section.

22 Sec. 481.07636. OPIOID PRESCRIPTION LIMITS. (a) In this  
23 section, "acute pain" means the normal, predicted, physiological  
24 response to a stimulus such as trauma, disease, and operative  
25 procedures. Acute pain is time limited. The term does not include:

26 (1) chronic pain;

27 (2) pain being treated as part of cancer care;

1           (3) pain being treated as part of hospice or other  
2 end-of-life care; or

3           (4) pain being treated as part of palliative care.

4           (b) For the treatment of acute pain, a practitioner may not:

5           (1) issue a prescription for an opioid in an amount  
6 that exceeds a 10-day supply; or

7           (2) provide for a refill of an opioid.

8           (c) Subsection (b) does not apply to a prescription for an  
9 opioid approved by the United States Food and Drug Administration  
10 for the treatment of substance addiction that is issued by a  
11 practitioner for the treatment of substance addiction.

12           (d) A dispenser is not subject to criminal, civil, or  
13 administrative penalties for dispensing or refusing to dispense a  
14 controlled substance under a prescription that exceeds the limits  
15 provided by Subsection (b).

16           SECTION 10. Section 481.128(a), Health and Safety Code, is  
17 amended to read as follows:

18           (a) A registrant or dispenser commits an offense if the  
19 registrant or dispenser knowingly:

20           (1) distributes, delivers, administers, or dispenses  
21 a controlled substance in violation of Subchapter C [~~Sections~~  
22 ~~481.070-481.075~~];

23           (2) manufactures a controlled substance not  
24 authorized by the person's Federal Drug Enforcement Administration  
25 registration or distributes or dispenses a controlled substance not  
26 authorized by the person's registration to another registrant or  
27 other person;

1           (3) refuses or fails to make, keep, or furnish a  
2 record, report, notification, order form, statement, invoice, or  
3 information required by this chapter;

4           (4) prints, manufactures, possesses, or produces an  
5 official prescription form without the approval of the board;

6           (5) delivers or possesses a counterfeit official  
7 prescription form;

8           (6) refuses an entry into a premise for an inspection  
9 authorized by this chapter;

10          (7) refuses or fails to return an official  
11 prescription form as required by Section 481.0755(k) [~~481.075(k)~~];

12          (8) refuses or fails to make, keep, or furnish a  
13 record, report, notification, order form, statement, invoice, or  
14 information required by a rule adopted by the director or the board;  
15 or

16          (9) refuses or fails to maintain security required by  
17 this chapter or a rule adopted under this chapter.

18          SECTION 11. Section 481.129(a), Health and Safety Code, is  
19 amended to read as follows:

20          (a) A person commits an offense if the person knowingly:

21               (1) distributes as a registrant or dispenser a  
22 controlled substance listed in Schedule I or II, unless the person  
23 distributes the controlled substance as authorized under the  
24 federal Controlled Substances Act (21 U.S.C. Section 801 et seq.);

25               (2) uses in the course of manufacturing, prescribing,  
26 or distributing a controlled substance a Federal Drug Enforcement  
27 Administration registration number that is fictitious, revoked,

1 suspended, or issued to another person;

2 (3) issues a prescription bearing a forged or  
3 fictitious signature;

4 (4) uses a prescription issued to another person to  
5 prescribe a Schedule II controlled substance;

6 (5) possesses, obtains, or attempts to possess or  
7 obtain a controlled substance or an increased quantity of a  
8 controlled substance:

9 (A) by misrepresentation, fraud, forgery,  
10 deception, or subterfuge;

11 (B) through use of a fraudulent prescription  
12 form; [~~or~~]

13 (C) through use of a fraudulent oral or  
14 telephonically communicated prescription; or

15 (D) through the use of a fraudulent electronic  
16 prescription; or

17 (6) furnishes false or fraudulent material  
18 information in or omits material information from an application,  
19 report, record, or other document required to be kept or filed under  
20 this chapter.

21 SECTION 12. Section 32.024, Human Resources Code, is  
22 amended by adding Subsection (z-2) to read as follows:

23 (z-2) The limits on prescription drugs and medications  
24 under the medical assistance program provided by Subsections (z)  
25 and (z-1) do not apply to a prescription for an opioid for the  
26 treatment of acute pain under Section 481.07636, Health and Safety  
27 Code.

1 SECTION 13. Subchapter B, Chapter 32, Human Resources Code,  
2 is amended by adding Section 32.03115 to read as follows:

3 Sec. 32.03115. REIMBURSEMENT FOR MEDICATION-ASSISTED  
4 TREATMENT FOR OPIOID OR SUBSTANCE USE DISORDER. (a) In this  
5 section, "medication-assisted opioid or substance use disorder  
6 treatment" means the use of methadone, buprenorphine, oral  
7 buprenorphine/naloxone, or naltrexone to treat opioid or substance  
8 use disorder.

9 (b) Notwithstanding Sections 531.072 and 531.073,  
10 Government Code, or any other law and subject to Subsections (c) and  
11 (d), the commission shall provide medical assistance reimbursement  
12 for medication-assisted opioid or substance use disorder treatment  
13 without requiring a recipient of medical assistance or health care  
14 provider to obtain prior authorization or precertification for the  
15 treatment, except as needed to minimize the opportunity for fraud,  
16 waste, or abuse.

17 (c) The duty to provide medical assistance reimbursement  
18 for medication-assisted opioid or substance use disorder treatment  
19 under Subsection (b) does not apply with respect to:

20 (1) a prescription for methadone;

21 (2) a recipient for whom medication-assisted opioid or  
22 substance use disorder treatment is determined to be medically  
23 contraindicated by the recipient's physician; or

24 (3) a recipient who is subject to an age-related  
25 restriction applicable to medication-assisted opioid or substance  
26 use disorder treatment.

27 (d) The commission may provide medical assistance

1 reimbursement for medication-assisted opioid or substance use  
2 disorder treatment only if the treatment is prescribed to a  
3 recipient of medical assistance by a licensed health care provider  
4 who is authorized to prescribe methadone, buprenorphine, oral  
5 buprenorphine/naloxone, or naltrexone.

6 (e) This section expires August 31, 2023.

7 SECTION 14. Section 554.051(a-1), Occupations Code, is  
8 amended to read as follows:

9 (a-1) The board may adopt rules to administer Sections  
10 [~~481.073,~~ 481.074, 481.075, 481.0755, 481.0756, 481.076,  
11 481.0761, 481.0762, 481.0763, 481.07635, 481.07636, 481.0764,  
12 481.0765, and 481.0766, Health and Safety Code.

13 SECTION 15. Section 565.003, Occupations Code, is amended  
14 to read as follows:

15 Sec. 565.003. ADDITIONAL GROUNDS FOR DISCIPLINE REGARDING  
16 APPLICANT FOR OR HOLDER OF NONRESIDENT PHARMACY LICENSE. Unless  
17 compliance would violate the pharmacy or drug statutes or rules in  
18 the state in which the pharmacy is located, the board may discipline  
19 an applicant for or the holder of a nonresident pharmacy license if  
20 the board finds that the applicant or license holder has failed to  
21 comply with:

22 (1) Section 481.074, [~~or~~] 481.075, 481.0755,  
23 481.0756, 481.076, 481.0761, 481.0762, 481.0763, 481.07635,  
24 481.07636, 481.0764, 481.0765, or 481.0766, Health and Safety Code;

25 (2) Texas substitution requirements regarding:

26 (A) the practitioner's directions concerning  
27 generic substitution;

1 (B) the patient's right to refuse generic  
2 substitution; or

3 (C) notification to the patient of the patient's  
4 right to refuse substitution;

5 (3) any board rule relating to providing drug  
6 information to the patient or the patient's agent in written form or  
7 by telephone; or

8 (4) any board rule adopted under Section 554.051(a)  
9 and determined by the board to be applicable under Section  
10 554.051(b).

11 SECTION 16. Sections 481.073, 481.074(o) and (p), and  
12 481.075(b), (c), (d), (f), (k), and (l), Health and Safety Code, are  
13 repealed.

14 SECTION 17. A person who holds a license, certification, or  
15 registration to prescribe or dispense a controlled substance issued  
16 before September 1, 2020, is required to take the continuing  
17 education course provided by Section 481.07635, Health and Safety  
18 Code, as added by this Act, not later than September 1, 2021.

19 SECTION 18. (a) In this section, "qualifying  
20 practitioner" has the meaning assigned by 21 U.S.C. Section  
21 823(g)(2)(G)(iii).

22 (b) Not later than November 1, 2019, the Health and Human  
23 Services Commission shall amend the commission's Medicaid  
24 Substance Use Disorder Services Medical Policy and any other  
25 provider or claims payment policy or manual necessary to authorize  
26 Medicaid medical benefits reimbursement for the prescribing of  
27 buprenorphine for the treatment of an opioid use disorder by an



1 advanced practice registered nurse recognized by the Texas Board of  
2 Nursing as a clinical nurse specialist, nurse anesthetist, or nurse  
3 midwife, provided that the advanced practice registered nurse:

4 (1) is a qualifying practitioner;

5 (2) has obtained a waiver from registration  
6 requirements as provided by 21 U.S.C. Section 823(g); and

7 (3) is acting under adequate physician supervision and  
8 a physician's delegation under Section [157.0512](#) or [157.054](#),  
9 Occupations Code.

10 SECTION 19. If before implementing any provision of this  
11 Act a state agency determines that a waiver or authorization from a  
12 federal agency is necessary for implementation of that provision,  
13 the agency affected by the provision shall request the waiver or  
14 authorization and may delay implementing that provision until the  
15 waiver or authorization is granted.

16 SECTION 20. This Act takes effect September 1, 2019.

---

President of the Senate

---

Speaker of the House

I certify that H.B. No. 2174 was passed by the House on April 25, 2019, by the following vote: Yeas 129, Nays 4, 1 present, not voting; and that the House concurred in Senate amendments to H.B. No. 2174 on May 24, 2019, by the following vote: Yeas 131, Nays 9, 3 present, not voting.

---

Chief Clerk of the House

I certify that H.B. No. 2174 was passed by the Senate, with amendments, on May 21, 2019, by the following vote: Yeas 28, Nays 3.

---

Secretary of the Senate

APPROVED: \_\_\_\_\_

Date

---

Governor